Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer
Interventions: BIOLOGICAL: ertumaxomab
Sponsor: Neovii Biotech